The low endogenous levels of OPG coupled with the significant lifetime risks of breast and ovarian cancer in BRCA mutation carriers, strongly support the use of an anti-RANKL monoclonal antibody like denosumab for the prevention of hereditary breast cancer while simultaneously maintaining bone density. This evidence concerns the gene TNFSF11 and ovarian carcinoma.